Drug intelligence / Profile preview

Stabilized Brain-Spect

Development stage: Unknown
Lead developer: Medi-Radiopharma
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Stabilized Brain-Spect (Tc-MR-15) is a radiopharmaceutical diagnostic agent developed by Medi-Radiopharma. It is a stabilized "cold kit" formulation of exametazime (hexamethylpropyleneamine oxime or HM-PAO) intended for labeling with technetium-99m (99mTc). Once labeled, the lipophilic 99mTc-exametazime complex crosses the blood-brain barrier and is converted into a hydrophilic form that is trapped in brain cells in proportion to regional cerebral blood flow. This stabilized version is designed to provide a longer shelf-life and better handling characteristics than conventional exametazime kits. It is primarily used for brain perfusion Single Photon Emission Computed Tomography (SPECT) imaging to evaluate regional cerebral blood flow and for the diagnostic radiolabeling of leukocytes (white blood cells) to localize infection or inflammation.

Brand names: Stabilized Brain-Spect
Other names: 99mTc-exametazime99mTc-HM-PAOstabilized 99mTc-HM-PAOstabilized99mTc-HM-PAOstabilized-99mTc-HM-PAOexametazimeHM-PAOhexamethylpropyleneamine oximeMedi-Radiopharma-brain (cerebral perfusion)-radiopharmaceutical (stabilized 99mTc-HM-PAO / exametazime cold kit)-intravenous injection-brain perfusion imaging / brain and cell labelling (diagnostic)

Beyond the preview

Go deeper on Stabilized Brain-Spect.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stabilized Brain-Spect.

Explore the full profile